Sawtooth Solutions LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,107 shares of the company’s stock after selling 497 shares during the quarter. Sawtooth Solutions LLC’s holdings in IDEXX Laboratories were worth $248,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in IDXX. LS Investment Advisors LLC raised its stake in shares of IDEXX Laboratories by 1.3% during the first quarter. LS Investment Advisors LLC now owns 3,424 shares of the company’s stock valued at $766,000 after purchasing an additional 45 shares in the last quarter. US Bancorp DE lifted its holdings in IDEXX Laboratories by 0.4% in the 1st quarter. US Bancorp DE now owns 12,253 shares of the company’s stock worth $2,739,000 after purchasing an additional 48 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 1.8% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 3,131 shares of the company’s stock worth $583,000 after buying an additional 56 shares during the last quarter. Northwestern Mutual Investment Management Company LLC lifted its holdings in shares of IDEXX Laboratories by 0.5% during the first quarter. Northwestern Mutual Investment Management Company LLC now owns 13,069 shares of the company’s stock worth $2,922,000 after buying an additional 60 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of IDEXX Laboratories by 1.8% during the fourth quarter. Thrivent Financial for Lutherans now owns 3,795 shares of the company’s stock valued at $706,000 after purchasing an additional 66 shares during the period. 87.76% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:IDXX traded down $1.02 during trading on Wednesday, hitting $262.91. 3,543 shares of the company were exchanged, compared to its average volume of 497,105. The company has a debt-to-equity ratio of 14.81, a current ratio of 1.01 and a quick ratio of 0.74. IDEXX Laboratories, Inc. has a 52-week low of $176.11 and a 52-week high of $271.34. The company has a market cap of $22.80 billion, a P/E ratio of 61.86 and a beta of 0.84.
In other IDEXX Laboratories news, Director Rebecca M. Henderson sold 8,790 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $241.57, for a total value of $2,123,400.30. Following the transaction, the director now directly owns 27,486 shares in the company, valued at approximately $6,639,793.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Jonathan W. Ayers sold 28,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $249.02, for a total transaction of $6,972,560.00. The disclosure for this sale can be found here. Insiders sold a total of 50,721 shares of company stock valued at $12,554,774 in the last ninety days. 2.70% of the stock is currently owned by insiders.
Several analysts have recently commented on IDXX shares. Guggenheim began coverage on IDEXX Laboratories in a report on Thursday, May 23rd. They set a “buy” rating and a $276.00 target price on the stock. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 7th. Canaccord Genuity raised their price target on IDEXX Laboratories from $255.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Finally, Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price objective for the company in a research report on Friday, May 3rd. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $256.71.
COPYRIGHT VIOLATION WARNING: This story was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://dakotafinancialnews.com/2019/06/12/idexx-laboratories-inc-nasdaqidxx-stake-decreased-by-sawtooth-solutions-llc.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: How is diluted EPS different from basic EPS?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.